Navigation Links
ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim
Date:3/16/2011

ADDISON, Texas, March 16, 2011 /PRNewswire/ -- ULURUInc. (NYSE Amex: ULU) announced today that it has filed an abbreviated 510(k) application with the U.S. Food and Drug Administration to expand Altrazeal®'s label claim to include the management and mitigation of pain.

The principal data supporting this 510(k) application is a randomized clinical study comparing Altrazeal® to Acquacel® Ag in skin graft donor sites. This amended label claim is also supported by clinical experience using Altrazeal® in various wound types including venous leg ulcers, second degree burns, geriatric wounds and numerous less common wound types.

In the randomized clinical study Altrazeal® when compared to Acquacel® Ag, a market leading product, used as the standard of care for skin graft donor sites at a number of major burn treatment centers, showed the following results:

  • At all 3 time points evaluated Altrazeal® demonstrated a statistically significant reduction in pain (P<0.0001) [Statistical significance is (P<0.05)]; and
  • Patients also reported a statistically significant improvement in comfort (P<0.001).

  • Significant pain reduction has also been reported when Altrazeal® has been used to treat venous leg ulcers.  Wound pain is a significant issue for venous leg ulcer patients with 80% of patients experiencing pain which can lead to poor patient compliance, fatigue, sleep disturbances and depression.

    In a group of patients treated with Altrazeal®, who had experienced venous leg ulcers for 3 – 27 years where all patients reported pain as an inhibiting factor with adherence to recommended compression treatment and the wounds had not decreased in size for several months:

  • All patients reported improvement in pain levels within 15 minutes of application (the patient with the 27 year old wound who previously reported continuous pain of 9-10 (0-10 scale) experienced immediate pain reduction to 2);
  • Patients increased compliance to the recommended treatment plan and these stagnated wounds healed; and
  • All patients reduced oral pain medication.

  • In addition, a group of second degree burn patients also reported a dramatic drop in pain upon application of Altrazeal® to their wounds. Prior to treatment with Altrazeal®, average pain scores were 8.2 (0-10 scale).  After application of Altrazeal®, pain was reduced to an average of 1.7 and during the treatment period the pain average was 0.4.

    Commenting on the 510(k) application, Kerry P. Gray, President and CEO of ULURU Inc., stated, "Altrazeal® is a scientifically engineered wound treatment product designed to fill a critical unmet clinical need in chronic wound care.  The Company believes that the substantial clinical data we have generated on wound healing and pain management justifies this unique label claim designation. No other wound treatment has demonstrated this major clinical advantage.  Patient compliance and improved patient comfort are critical components in the treatment of chronic wounds. Achieving this amended label claim will be a significant competitive advantage and further differentiate Altrazeal® from other wound products."

    The filing of this application is an integral part of the Company's ongoing product line extension strategy to provide a value added portfolio of products to assist wound care professionals to improve clinical outcomes, as well as provide patients with compliance and comfort benefits.

    Mr. Gray added, "In the near term we intend to file additional 510(k) applications and further product line extensions.  Also, we intend to initiate an additional randomized clinical study to prove healing benefits associated with Altrazeal® that could enable us to further expand the label claim and differentiation of Altrazeal®."

    AboutULURUInc.:ULURUInc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.

    This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended including the results of our clinical trial, our belief that the substantial clinical data we have generated on wound healing and pain management justifies this unique label claim designation, our belief that achieving this amended label claim will be a significant competitive advantage and further differentiate Altrazeal® from other wound products, and further intended 510(k) filings that are anticipated. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by us with the Securities and Exchange Commission.Contact: CompanyKerry P. Gray President&CEOTerry K. Wallberg Vice President & CFO(214) 905-5145
    '/>"/>

    SOURCE ULURU Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex
    2. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
    3. ULURU Inc. to Raise $500,000 in Registered Direct Offering
    4. ULURU Inc. Reports Third Quarter 2010 Financial Results
    5. ULURU Inc. Provides Altrazeal® Clinical Update
    6. ULURU Inc. Announces Conference Call
    7. ULURU Inc. Reports Second Quarter 2010 Financial Results
    8. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
    9. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
    10. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
    11. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
    (Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
    (Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
    Breaking Medicine Technology:
    (Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
    (Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
    (Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
    (Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
    (Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
    Breaking Medicine News(10 mins):